<?xml version='1.0' encoding='utf-8'?>
<document id="27086359"><sentence text="Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives."><entity charOffset="60-70" id="DDI-PubMed.27086359.s1.e0" text="Sucralfate" /></sentence><sentence text="Sucralfate, a complex of aluminium hydroxide with sulfated sucrose, forms a strong gastrointestinal tract (GIT) mucosal barrier with excellent anti-ulcer property"><entity charOffset="0-10" id="DDI-PubMed.27086359.s2.e0" text="Sucralfate" /><entity charOffset="25-44" id="DDI-PubMed.27086359.s2.e1" text="aluminium hydroxide" /><pair ddi="false" e1="DDI-PubMed.27086359.s2.e0" e2="DDI-PubMed.27086359.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27086359.s2.e0" e2="DDI-PubMed.27086359.s2.e1" /></sentence><sentence text=" Because sucralfate does not undergo any significant oral absorption, sucralfate resides in the GIT for a considerable length of time"><entity charOffset="70-80" id="DDI-PubMed.27086359.s3.e0" text="sucralfate" /></sentence><sentence text=" The unabsorbed sucralfate may alter the pharmacokinetics of the oral drugs by impeding its absorption and reducing the oral bioavailability"><entity charOffset="16-26" id="DDI-PubMed.27086359.s4.e0" text="sucralfate" /></sentence><sentence text=" Because of the increased use of sucralfate, it was important to provide a reappraisal of the published clinical drug-drug interaction studies of sucralfate with scores of drugs"><entity charOffset="33-43" id="DDI-PubMed.27086359.s5.e0" text="sucralfate" /><entity charOffset="146-156" id="DDI-PubMed.27086359.s5.e1" text="sucralfate" /><pair ddi="false" e1="DDI-PubMed.27086359.s5.e0" e2="DDI-PubMed.27086359.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27086359.s5.e0" e2="DDI-PubMed.27086359.s5.e1" /></sentence><sentence text=" This review covers several category of drugs such as non-steroidal anti-inflammatory drugs, fluoroquinolones, histamine H2-receptor blockers, macrolides, anti-fungals, anti-diabetics, salicylic acid derivatives, steroidal anti-inflammatory drugs and provides pharmacokinetic data summary along with study design, objectives and key remarks"><entity charOffset="93-109" id="DDI-PubMed.27086359.s6.e0" text="fluoroquinolones" /><entity charOffset="111-120" id="DDI-PubMed.27086359.s6.e1" text="histamine" /><entity charOffset="185-199" id="DDI-PubMed.27086359.s6.e2" text="salicylic acid" /><pair ddi="false" e1="DDI-PubMed.27086359.s6.e0" e2="DDI-PubMed.27086359.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27086359.s6.e0" e2="DDI-PubMed.27086359.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27086359.s6.e0" e2="DDI-PubMed.27086359.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27086359.s6.e1" e2="DDI-PubMed.27086359.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27086359.s6.e1" e2="DDI-PubMed.27086359.s6.e2" /></sentence><sentence text=" While the loss of oral bioavailability was significant for the fluoroquinolone class, it generally varied for other classes of drugs, suggesting that impact of the co-administration of sucralfate is manageable in clinical situations"><entity charOffset="64-79" id="DDI-PubMed.27086359.s7.e0" text="fluoroquinolone" /><entity charOffset="186-196" id="DDI-PubMed.27086359.s7.e1" text="sucralfate" /><pair ddi="false" e1="DDI-PubMed.27086359.s7.e0" e2="DDI-PubMed.27086359.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27086359.s7.e0" e2="DDI-PubMed.27086359.s7.e1" /></sentence><sentence text=" Given the technology advancement in formulation development, it may be in order feasible to develop appropriate formulation strategies to either avoid or minimize the absorption-related issues when co-administered with sucralfate"><entity charOffset="220-230" id="DDI-PubMed.27086359.s8.e0" text="sucralfate" /></sentence><sentence text=" It is recommended that consideration of both in vitro and preclinical studies may be in order to gauge the level of interaction of a drug with sucralfate"><entity charOffset="144-154" id="DDI-PubMed.27086359.s9.e0" text="sucralfate" /></sentence><sentence text=" Such data may aid in the development of appropriate strategies to navigate the co-administration of sucralfate with other drugs in this age of polypharmacy"><entity charOffset="101-111" id="DDI-PubMed.27086359.s10.e0" text="sucralfate" /></sentence><sentence text=" " /></document>